Impact of TP53 mutations in acute myeloid leukemia patients treated with azacitidine

Impact of TP53 mutations in acute myeloid leukemia patients treated with azacitidine

Show other versions (1)

Hypomethylating agents are a classical frontline low-intensity therapy for older patients with acute myeloid leukemia. Recently, TP53 gene mutations have been described as a potential predictive biomarker of better outcome in patients treated with a ten-day decitabine regimen., However, functional c...

Full description

Bibliographic Details
Main Authors: Pierre Bories, Naïs Prade, Stéphanie Lagarde, Bastien Cabarrou, Laetitia Largeaud, Julien Plenecassagnes, Isabelle Luquet, Véronique De Mas, Thomas Filleron, Manon Cassou, Audrey Sarry, Luc-Matthieu Fornecker, Célestine Simand, Sarah Bertoli, Christian Recher, Eric Delabesse, Francesco Bertolini
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2020-01-01
Series:PLoS ONE
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7529302/?tool=EBI

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7529302/?tool=EBI

Similar Items